Skip to main content

previous disabled Page of 2
and
  1. Article

    Open Access

    SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade

    This study aimed to investigate the relationship between signal regulatory protein gamma (SIRPG) and tumor immune microenvironment phenotypes or T cell mediated-adaptive antitumor immunity, and its predictive ...

    Libo Luo, Minlin Jiang, Hong Wu, Yiqiang Liu in Cancer Immunology, Immunotherapy (2024)

  2. Article

    Open Access

    Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study

    The combination of immune checkpoint inhibitors and antiangiogenic agents has been effective in treating multiple cancers. This was further explored in an open-label, multicenter phase 2 basket study (NCT04346...

    Shengxiang Ren, Anwen **ong, Jia Yu, **cheng Wang in Cancer Immunology, Immunotherapy (2024)

  3. Article

    Open Access

    Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment

    KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, the response to immunotherapy is heterogeneous owing to the distinct co-occurring genomic alterations. KRAS/LKB1 co-mutated lung adenoc...

    Meng Qiao, Fei Zhou, **nyu Liu, Tao Jiang in Experimental Hematology & Oncology (2024)

  4. Article

    Open Access

    Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway

    Fibronectin, an extracellular matrix protein, has been reported to be associated with heterogeneous cancer stemness, angiogenesis and progression in multiple cancer types. However, the roles and the underlying...

    Fei Zhou, Jianguo Sun, Lingyun Ye, Tao Jiang, Wei Li in Experimental Hematology & Oncology (2023)

  5. Article

    Open Access

    Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials

    Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) showed moderate ob...

    Shiqi Mao, Shuo Yang, **nyu Liu, in Experimental Hematology & Oncology (2023)

  6. Article

    Open Access

    Designing highly multiplex PCR primer sets with Simulated Annealing Design using Dimer Likelihood Estimation (SADDLE)

    One major challenge in the design of highly multiplexed PCR primer sets is the large number of potential primer dimer species that grows quadratically with the number of primers to be designed. Simultaneously,...

    Nina G. **e, Michael X. Wang, ** Song, Shiqi Mao, Yifan Wang in Nature Communications (2022)

  7. Article

    Open Access

    On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

    Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma ...

    Tao Jiang, Jianhua Chen, **ngxiang Xu, Ying Cheng, Gongyan Chen in Molecular Cancer (2022)

  8. No Access

    Article

    ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC

    Immune checkpoint inhibitors (ICI) monotherapy was standard of care in second-line treatment of patients with advance non-small cell lung cancer (NSCLC). This study aims to investigate the efficacy of ICI plus...

    Shiqi Mao, Fei Zhou, Yiwei Liu, Shuo Yang, Bin Chen in Cancer Immunology, Immunotherapy (2022)

  9. Article

    Open Access

    Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

    This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC. Patients...

    Tao Jiang, **yang Wang, Jie Zhang in Signal Transduction and Targeted Therapy (2021)

  10. Article

    Open Access

    Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer

    Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor microenvironment together determine disease progression, as well as response to or escape from treatment. To map the cell ...

    Fengying Wu, Jue Fan, Yayi He, Anwen **ong, Jia Yu, Yixin Li in Nature Communications (2021)

  11. Article

    Open Access

    Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma

    Characterizing the evolutionary trajectory and immune profiling of brain metastasis (BM) may provide insights in the development of novel therapeutic strategies. Here, we performed whole-exome sequencing and m...

    Tao Jiang, Yan Yan, Kun Zhou, Chunxia Su, Shengxiang Ren, Nan Li in npj Precision Oncology (2021)

  12. Article

    Open Access

    Multi-cancer blood testing combined with PET-CT: road for hope to screen for cancer and guide intervention

    Tao Jiang, Shengxiang Ren, Caicun Zhou in Signal Transduction and Targeted Therapy (2020)

  13. Article

    Open Access

    Tumor neoantigens: from basic research to clinical applications

    Tumor neoantigen is the truly foreign protein and entirely absent from normal human organs/tissues. It could be specifically recognized by neoantigen-specific T cell receptors (TCRs) in the context of major hi...

    Tao Jiang, Tao Shi, Henghui Zhang, Jie Hu, Yuanlin Song in Journal of Hematology & Oncology (2019)

  14. Article

    Open Access

    Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

    To depict the genomic landscape of Chinese early-stage lung squamous cell carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 expression, and immune infiltrates.

    Tao Jiang, **peng Shi, Zhengwei Dong, Likun Hou in Journal of Hematology & Oncology (2019)

  15. Article

    Open Access

    Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction

    Platelet glycoprotein Ibα (GPIbα) extracellular domain, which is part of the receptor complex GPIb-IX-V, plays an important role in tumor metastasis. However, the mechanism through which GPIbα participates in ...

    Yingxue Qi, Wenchun Chen, **nyu Liang, Ke Xu in Journal of Hematology & Oncology (2018)

  16. No Access

    Article

    Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis

    To investigate the association between pretreatment blood neutrophil-to-lymphocyte ratio (NLR) and clinical outcomes for advanced-stage cancer patients treated with immunotherapy.

    Tao Jiang, Meng Qiao, Chao Zhao, Xuefei Li in Cancer Immunology, Immunotherapy (2018)

  17. Article

    Open Access

    Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

    HER2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers(NSCLC) and HER2-directed therapies have shown promising results in this unique population, while little is known about it...

    Yan Wang, Shijia Zhang, Fengying Wu, **g Zhao, Xuefei Li, Chao Zhao in BMC Cancer (2018)

  18. Article

    Open Access

    Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers

    CD73 is one of the critical component in the formation of immunosuppressive microenvironment in cancers. We aimed to provide an overview of the current status of CD73 expression and its relationship with clini...

    Tao Jiang, **aofeng Xu, Meng Qiao, Xuefei Li, Chao Zhao, Fei Zhou in BMC Cancer (2018)

  19. Article

    Open Access

    Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases

    Whether bisphosphonates could enhance the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation and bone metastas...

    Guowei Zhang, Ruirui Cheng, Zengli Zhang, Tao Jiang, Shengxiang Ren in Scientific Reports (2017)

  20. Article

    Open Access

    Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China

    Human epidermal growth factor receptor (HER)-2 is a driver gene in non-small cell lung cancer (NSCLC). The present study evaluated the mutation rate of HER-2 within the wild-type epidermal growth factor receptor ...

    Xuefei Li, Chao Zhao, Chunxia Su, Shengxiang Ren, **aoxia Chen, Caicun Zhou in BMC Cancer (2016)

previous disabled Page of 2